My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
uniQure N.V. - Ordinary Shares
(NQ:
QURE
)
58.58
-1.41 (-2.35%)
Streaming Delayed Price
Updated: 1:32 PM EDT, Oct 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,267,569
Open
59.99
Bid (Size)
58.44 (1)
Ask (Size)
58.72 (1)
Prev. Close
59.99
Today's Range
57.66 - 60.38
52wk Range
5.350 - 65.14
Shares Outstanding
54,865,673
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Why Is Protalix BioTherapeutics Stock Falling On Friday?
Today 11:23 EDT
EMA issues a negative opinion on Protalix and Chiesi's Elfabrio revised dosing for Fabry disease, citing insufficient data to confirm efficacy.
Via
Benzinga
Cramer Warns On One Chip Stock, Says Broadcom Is The Better Bet
October 06, 2025
Jim Cramer recommends caution with Ambiq Micro (AMBQ) and suggests Broadcom (AVGO). He dislikes Albertsons (ACI) and advises selling some Dillard's (DDS).
Via
Benzinga
Performance
YTD
+224.5%
+224.5%
1 Month
+304.8%
+304.8%
3 Month
+285.4%
+285.4%
6 Month
+350.6%
+350.6%
1 Year
+805.4%
+805.4%
More News
Read More
QURE: Why Analysts See Up to 63% Upside After 250% Single-Day Pop
October 03, 2025
Via
MarketBeat
10 Health Care Stocks Whale Activity In Today's Session
October 01, 2025
Via
Benzinga
uniQure Announces Closing of Upsized Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares
September 29, 2025
From
uniQure Inc.
Via
GlobeNewswire
Benzinga Bulls And Bears: Oracle, Costco, NIO — And Wall Street Snaps Its Slide
September 27, 2025
Via
Benzinga
uniQure Announces Pricing of Upsized $300 Million Public Offering
September 25, 2025
From
uniQure Inc.
Via
GlobeNewswire
UniQure Stock's 248% Blastoff Was Just The Start — Ask Wall Street
September 25, 2025
Via
Benzinga
CrowdStrike To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Thursday
September 25, 2025
Via
Benzinga
uniQure Stock Jumps On Positive News, But Risks Remain
September 25, 2025
Via
Benzinga
Wall Street Pauses AI Frenzy as Oracle Seeks $15B in Fresh Funding
September 25, 2025
Via
Chartmill
Topics
Artificial Intelligence
Alibaba, Intel, Uniqure, Tesla And Opendoor: Why These 5 Stocks Are On Investors' Radars Today
September 24, 2025
Via
Benzinga
UniQure Stock Hits 5-Year High As Analysts Hail Huntington’s Therapy Data — Retail Spots ‘Diamond In Rough Of Biotech’
September 24, 2025
Via
Stocktwits
uniQure Announces $200 Million Proposed Public Offering
September 24, 2025
From
uniQure Inc.
Via
GlobeNewswire
Nasdaq Down Over 100 Points; US Crude Oil Stocks Fall
September 24, 2025
Via
Benzinga
What's Going On With UniQure Stock Wednesday?
September 24, 2025
Via
Benzinga
Lithium Americas, Alibaba, uniQure, IREN, Cidara: Stocks Making The Biggest Moves Today
September 24, 2025
Via
Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
September 24, 2025
Via
Benzinga
A Cure For Huntington's Disease? UniQure Launches More Than 240%.
September 24, 2025
Via
Investor's Business Daily
uniQure Stock Doubles On Promising Data From Huntington's Disease Trial
September 24, 2025
Via
Benzinga
uniQure Stock Rises Pre-Market After Investigational Huntington’s Disease Drug Slows Disease In Trial
September 24, 2025
Via
Stocktwits
uniQure Announces Refinancing of Existing $50 Million Debt and Securing Up to an Additional $125 Million in Non-Dilutive Funding
September 24, 2025
From
uniQure Inc.
Via
GlobeNewswire
uniQure Announces Positive Topline Results from Pivotal Phase I/II Study of AMT-130 in Patients with Huntington’s Disease
September 24, 2025
From
uniQure Inc.
Via
GlobeNewswire
uniQure's Investigational Gene Therapy Shows Promising Efficacy With Manageable Safety Risks For Fabry Disease
September 05, 2025
Via
Benzinga
uniQure Announces Initial AMT-191 Phase I/IIa Data Showing Sustained Increases in α-Gal A Enzyme Activity in Patients with Fabry Disease
September 05, 2025
From
uniQure Inc.
Via
GlobeNewswire
Frequently Asked Questions
Is uniQure N.V. - Ordinary Shares publicly traded?
Yes, uniQure N.V. - Ordinary Shares is publicly traded.
What exchange does uniQure N.V. - Ordinary Shares trade on?
uniQure N.V. - Ordinary Shares trades on the Nasdaq Stock Market
What is the ticker symbol for uniQure N.V. - Ordinary Shares?
The ticker symbol for uniQure N.V. - Ordinary Shares is QURE on the Nasdaq Stock Market
What is the current price of uniQure N.V. - Ordinary Shares?
The current price of uniQure N.V. - Ordinary Shares is 58.58
When was uniQure N.V. - Ordinary Shares last traded?
The last trade of uniQure N.V. - Ordinary Shares was at 10/17/25 01:32 PM ET
What is the market capitalization of uniQure N.V. - Ordinary Shares?
The market capitalization of uniQure N.V. - Ordinary Shares is 3.21B
How many shares of uniQure N.V. - Ordinary Shares are outstanding?
uniQure N.V. - Ordinary Shares has 3B shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.